AbbVie, a global biopharmaceutical company, announced today that data from multiple clinical trials evaluating venetoclax, a first-in-class oral B-cell lymphoma-2 (BCL-2) inhibitor, will be presented at the 22nd European Hematology Association (EHA) Annual Congress, June 22-25, in Madrid. Investigational data will be presented from 15 studies evaluating venetoclax across some of the most common hematologic malignancies, including chronic lymphocytic leukemia, multiple myeloma, acute myeloid leukemia and non-Hodgkin lymphoma.
VENCLYXTO monotherapy is approved in the EU for the treatment of CLL in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor; and for the treatment of CLL in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor. VENCLYXTO is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S.
“AbbVie is committed to investigating the safety and efficacy of venetoclax. The data being presented at EHA reinforce this commitment and underscore our mission to develop and deliver therapies that address unmet needs in a selected set of debilitating hematologic malignancies and have a remarkable impact on the lives of people affected by cancer,” said Gary Gordon, M.D., Ph.D., vice president, oncology clinical development, AbbVie.